<DOC>
	<DOCNO>NCT03070548</DOCNO>
	<brief_summary>This study evaluate mass balance talazoparib single dose talazoparib .</brief_summary>
	<brief_title>A Study Talazoparib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Patients participate study clinically significant toxicity may eligible continue treatment separate extension protocol discussion Principal Investigator obtain Sponsor permission..</detailed_description>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>1 . At least 18 year age willing able provide inform consent . 2 . Histologically confirm advanced solid tumor ( limited platinumresistant ovarian carcinoma , cervical adenocarcinoma , small cell lung carcinoma triplenegative breast cancer ) judge Investigator appropriate standard therapy . 3 . Eastern CoOperative Oncology Group ( ECOG ) performance status ≤ 2 screen Day 1 . 4 . Expected life expectancy ≥ 3 month . 5 . Able swallow study drug comply study requirement . 6 . Female subject may enrol consider childbearing potential , postmenopausal , childbearing potential use highly effective form contraception , female subject donate eggs time point IMP administration least 45 day thereafter . 7 . Males partner childbearing potential may enrol use condom sex pregnant woman woman childbearing potential 21 day first dose study drug 105 day last dose study drug , male donate sperm time point study drug administration least 105 day thereafter . 8 . Female patient must breastfeed screen study participation 45 day last dose study drug . 9 . Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure . 1 . Treatment within 14 week five halflive prior dose type systemic anticancer therapy investigational agent , whichever longer . 2 . Major surgery within 8 week screen . 3 . Serious accompany disorder impair organ function . 4 . Symptomatic impend spinal cord compression cauda equina syndrome . 5 . Nonhealing wound , ulcer , bone fracture , include pathological bone fracture cause preexistent pathological bone lesion . 6 . Known myelodysplastic syndrome . 7 . Patients follow serology exclude : HBsAg+ antiHBc+ ; HCV+ ; HIV+ . 8 . Serious unstable medical condition interferes ability tolerate treatment assessment associate protocol . 9 . Gastrointestinal disorder affect absorption . 10 . Known hypersensitivity talazoparib solution component . 11 . Use strong Pgp inhibitor , strong Pgp inducer , strong inhibitor BRCP within 7 day 5 halflives , whichever longer , Day 1 . 12 . Any condition reason interfere ability participate study , cause undue risk , complicate interpretation safety data , opinion Investigator Sponsor ( e.g . noncompliance , excessive alcohol consumption , intake drug abuse unless drug medically indicate [ e.g . opiates pain relief ] ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>